Table 4. Haematological and non-haematological adverse events of grade 3–4 during CCRT period.
| Adverse events | Paccagnella et al. 201018 | Chen et al. 201119 | Haddad et al. 201320 | Cohen et al. 201421 | Hitt et al. 201422 | Total | Risk ratios [95% CI] | P-values |
|---|---|---|---|---|---|---|---|---|
| Haematologic | ||||||||
| Anemia | 2/43 vs 0/49 | 3/60 vs 1/60 | NR | 8/124 vs 4/133 | 5/106 vs 5/118 | 18/333 vs 10/360 | 1.91 [0.91, 4.02] | 0.09 |
| Thrombocytopenia | 2/43 vs 2/49 | 3/60 vs 3/60 | NR | 4/124 vs 2/133 | 12/106 vs 5/118 | 21/333 vs 12/360 | 1.90 [0.95, 3.79] | 0.07 |
| Neutropenia | 2/43 vs 4/49 | 5/60 vs 6/60 | NR | 4/124 vs 2/133 | 32/106 vs 24/118 | 43/333 vs 36/360 | 1.31 [0.88, 1.95] | 0.19 |
| Febrile neutropenia | 0/43 vs 0/49 | NR | 16/70 vs 1/75 | NR | 5/106 vs 1/118 | 5/149 vs 1/167 | 11.41 [2.71, 48.03] | 0.0009* |
| Leukopenia | 3/43 vs 6/49 | 7/60 vs 8/60 | NR | 32/124 vs 15/133 | 16/106 vs 14/118 | 57/333 vs 43/360 | 1.46 [1.01, 2.10] | 0.04* |
| Non-haematologic | ||||||||
| Fatigue | 1/43 vs 4/49 | NR | NR | 6/124 vs 4/133 | 7/106 vs 4/118 | 14/273 vs 12/300 | 1.29 [0.60, 2.74] | 0.51 |
| Nausea/Vomiting | 0/43 vs 0/49 | 0/60 vs 0/60 | NR | 11/124 vs 9/133 | 8/106 vs 16/118 | 19/333 vs 25/360 | 0.85 [0.37, 1.96] | 0.70 |
| Mucositis | 12/43 vs 18/49 | 19/60 vs 18/60 | 33/70 vs 12/75 | 121/124 vs 119/133 | 52/106 vs 39/118 | 237/403 vs 206/435 | 1.30 [0.86, 1.97] | 0.22 |
| Dermatitis | 8/43 vs 6/49 | 10/60 vs 9/60 | NR | 22/124 vs 32/133 | NR | 40/227 vs 47/242 | 0.91 [0.62, 1.33] | 0.62 |
| Pain | 4/43 vs 5/49 | NR | 2/70 vs 9/75 | 13/124 vs 8/133 | NR | 19/237 vs 22/257 | 1.42 [0.71, 2.86] | 0.74 |
| Dysphagia | 9/43 vs 10/49 | NR | NR | 15/124 vs 20/133 | 9/106 vs 5/118 | 33/273 vs 35/300 | 1.04 [0.67, 1.61] | 0.87 |
| Weight loss | 2/43 vs 1/49 | 3/60 vs 2/60 | NR | 2/124 vs 5/133 | NR | 7/227 vs 8/242 | 0.93 [0.34, 2.52] | 0.88 |
NR:Not report Vs:Versus (IC + CCRT vs CCRT) * P < 0.05.